Physician

Dael Ron Geft, M.D.

According to 2025 Medicare claims, Dael Geft, M.D. (NPI: 1265617187) practices advanced heart failure and transplant cardiology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is CEDARS-SINAI MEDICAL CARE FOUNDATION (NPI: 1316984388; TIN: 954457756) and primary practice location at 90211-2930. Geft is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Geft's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 534 traditional Medicare patients, billed 1,994 HCPCS/CPT codes, and received $162,940 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 1,951 prescription claims across 252 beneficiaries totaling $1,203,379 in drug costs, led by Vyndaqel (Tafamidis Meglumine). DME data shows 79 claims. Open Payments data shows 4 records totaling $24,764. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $278,292 to $1,203,379. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $9,540 and ending at $13,445.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	389	1,383	$133,962
2016	338	1,342	$120,412
2017	363	1,383	$118,198
2018	380	1,484	$118,261
2019	378	1,380	$111,111
2020	372	1,487	$116,509
2021	426	1,475	$124,755
2022	447	1,624	$137,000
2023	520	1,962	$163,878
2024	534	1,994	$162,940

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	100	1,178	$278,292
2016	105	942	$83,484
2017	92	662	$31,211
2018	135	855	$80,122
2019	173	1,047	$154,810
2020	159	1,083	$300,544
2021	177	1,479	$269,581
2022	207	1,453	$737,449
2023	233	1,765	$787,223
2024	252	1,951	$1,203,379

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	26	$2,307
2017	N/R	107	$9,314
2018	N/R	77	$6,817
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	11	$20
2022	N/R	36	$43,250
2023	N/R	112	$42,552
2024	N/R	79	$58,484

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	154	164	$160
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	301	490	$101
99442	Telephone medical discussion with physician, 11-20 minutes	103	128	$77
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	118	122	$12
36415	Insertion of needle into vein for collection of blood sample	102	144	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndaqel	Tafamidis Meglumine	14	420	$290,538
Eliquis	Apixaban	113	6,850	$138,407
Repatha Sureclick	Evolocumab	136	5,734	$108,985
Ambrisentan	Ambrisentan	13	390	$93,320
Entresto	Sacubitril/Valsartan	56	2,941	$57,492

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J3285	Injection, treprostinil, 1 mg	N	N/R	16	$45,200
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	15	$8,792
K0455	Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol)	Y	N/R	11	$2,928
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$764
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	13	$448

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$54	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$24,710	Cedars-Sinai Medical Center
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Dael Ron Geft, M.D.?

Tedicare shows public-source Medicare data for Dael Ron Geft, M.D. (NPI 1265617187), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Dael Ron Geft, M.D. have ACO affiliation data?

Dael Ron Geft, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Dael Ron Geft, M.D.?

Dael Ron Geft, M.D. is linked to CEDARS-SINAI MEDICAL CARE FOUNDATION (billing NPI 1316984388) in the available physician profile data.

Does Dael Ron Geft, M.D. have Open Payments data?

Dael Ron Geft, M.D. has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.